ACTION ON FISTULA™ to transform 4,500 lives by 2020
ACTION ON FISTULA™ is supported by a grant to the Fistula Foundation by Astellas Pharma Europe Limited (“Astellas”).
- ACTION ON FISTULA™ has already treated over 2,500 women with obstetric fistula
- Astellas Pharma supports Fistula Foundation in its second phase of the programme to work towards ending obstetric fistula
Chertsey, England [23 May, 2017] On International Day to End Obstetric Fistula, Astellas Pharma Europe Ltd (“Astellas”) pledged its support to the Fistula Foundation as the second phase of ACTION ON FISTULA™ launches with an ambitious target to treat 4,500 women with obstetric fistula in Kenya by 2020.
ACTION ON FISTULA™, supported by a grant from Astellas, is a programme set up by the Fistula Foundation in 2014 with the initial objective to transform the lives of more than 1,200 women in Kenya living with fistula: an injury caused by prolonged obstructed labour, leading to faecal or urinary incontinence or both. It most commonly occurs among women who live in rural communities in low-resource countries, who are not aware that help is available or are unable to reach a hospital.
The programme has already:
- given over 2,500 Kenyan women with obstetric fistula life changing reconstructive surgery
- significantly increased surgical capacity in Kenya to treat the condition by training six fistula surgeons
- set up a fistula treatment network to extend access to services, with six treatment centres enrolled and providing fistula surgeries on a routine basis
- built a major outreach programme to identify and bring women in for treatment.
From May 2017 – April 2020 ACTION ON FISTULA™ will:
- provide surgeries to an additional 2,000 women with fistula and continue to build capacity in Kenya to deliver ongoing treatment
- extend its treatment network to up to eight treatment centres
- train a further six surgeons at the Gynocare Women’s and Fistula Hospital in Kenya, including clinicians from outside the country to build capacity across sub-Saharan Africa and South-East Asia
- train 10 fistula nurses to support women through their treatment journey
- establish 20 support groups throughout Kenya to provide recovering fistula patients with psychosocial assistance, economic empowerment and income-generating activities to help enable survivors to return to their communities.
Kate Grant, CEO, Fistula Foundation, comments, “Our partnership with Astellas has enabled us to transform the treatment landscape in Kenya, from hospitals that worked largely in a vacuum, to a country-wide network of six facilities offering regular fistula treatment. The results have been incredible, enabling us to treat more than double the number of women we initially set out to help.”
Yukio Matsui, Chief Commercial Officer, Astellas Pharma Inc., said, “We are enormously proud of what the programme has achieved in such a small space of time. Through the commitment and skill of Fistula Foundation working to train surgeons and mobilise outreach teams on the ground in Kenya, ACTION ON FISTULA™ has transformed the lives of more than double the number of women it set out to. This is truly remarkable."
“Over the next three years we have set ourselves an ambitious goal of treating many more women with this devastating condition and building an even stronger treatment infrastructure in Kenya so the legacy of ACTION ON FISTULA™ lasts for many years to come.”
Whilst virtually eradicated in developed countries, the United Nations Population Fund (UNFPA) estimates 3,000 new cases of obstetric fistula occur annually in Kenya, with approximately one to two fistulas for every 1,000 deliveries6.
Women with fistula are often subject to severe social stigma due to odour, which is constant and humiliating, and in many cases drives the patients’ family, friends and neighbours away. Stigmatised, these women are also often denied access to education and employment and left to live lives of isolation and poverty.
ACTION ON FISTULA™ was recognised at the 2017 Better Society Awards for its work with Fistula Foundation in the ‘Partnership with an International Charity’ category and the 2017 Communiqué Awards for the ‘Excellence in Corporate Social Responsibility’ category.
Astellas is committed to the long-term sustainability of society by improving Access to Health and medical solutions, fostering scientific advancement and enhancing the health of our communities. ACTION ON FISTULA™ is a flagship programme of Access Accelerated, a multi-stakeholder collaboration focused on improving non-communicable disease care supported by Astellas Pharma Inc.